Initially invented by Sofradim, a French company acquired by Covidien, this product did not fit into Covidienís product mix. The IP Factoryís review revealed that although traditional gastric banding was losing favor as a technique to control or reverse obesity, this product responded to many of the negatives with the traditional bands. Based on a globally growing problem with obesity it was felt that there was a significant market for this product. In addition, the absorbable polymer lends itself to other products that could be used in the body.
The IP Factory is currently determining the clinical development plan for a product launch in Europe and also the United States. With revenue coming in from non-US sales, a newly formed company can pursue the clinical trials that are needed for US approval as well as looking at other products for which the absorbable polymer could serve as the base.